Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Updates on Recent Advances in the Therapy of Adult Psoriatic Disease

Abstract

Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with various joint and skin manifestations and multiple associated comorbidities. The management of PsA is important not only in controlling disease activity and preventing subsequent damage but also in improving the quality of life and reducing mortality. Over the years, numerous drugs have been introduced into the therapeutic armamentarium of the disease. While non-steroidal anti-inflammatory drugs (NSAIDs) and conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) have contributed to management, it was not until the advent of biologics (and later on targeted synthetic DMARDs) that therapy was revolutionized, with the achievement of significantly better clinical and radiographic outcomes. Several drugs and treatment approaches are currently being tested in clinical trials at different phases. Despite all the success, there are still various challenges and unmet needs in the field of PsA, reflected by difficult-to-treat disease course, secondary failure of therapy, and lack of consensus on accepted treatment withdrawal protocols, among others. In this review, we have discussed the most recent advances in the therapy of psoriatic disease, with a particular focus on phase III studies completed (or ongoing) since 2020. We also mentioned the challenges and unmet needs in our clinical practice, which we expect current and future research to provide answers to.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971339350240830104424
2025-01-01
2025-01-24

  • From This Site

    /content/journals/crr/10.2174/0115733971339350240830104424
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Coates L.C. Helliwell P.S. Psoriatic arthritis: state of the art review. Clin. Med. (Lond.) 2017 17 1 65 70 10.7861/clinmedicine.17‑1‑65 28148584
    [Google Scholar]
  2. Coates L.C. Soriano E.R. Corp N. Bertheussen H. Callis Duffin K. Campanholo C.B. Chau J. Eder L. Fernández-Ávila D.G. FitzGerald O. Garg A. Gladman D.D. Goel N. Helliwell P.S. Husni M.E. Jadon D.R. Katz A. Laheru D. Latella J. Leung Y.Y. Lindsay C. Lubrano E. Mazzuoccolo L.D. Mease P.J. O’Sullivan D. Ogdie A. Olsder W. Palominos P.E. Schick L. Steinkoenig I. de Wit M. van der Windt D.A. Kavanaugh A. Campanholo C. Fitzgerald O. Gladman D. Helliwell P. Husni M.E. Laheru D. Leung Y-Y. Lubrano E. Mazzuoccolo L.D. Mease P.J. Ogdie A. Palominos P.E. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat. Rev. Rheumatol. 2022 18 8 465 479 10.1038/s41584‑022‑00798‑0 35761070
    [Google Scholar]
  3. Husni M.E. Comorbidities in Psoriatic Arthritis. Rheum. Dis. Clin. North Am. 2015 41 4 677 698 10.1016/j.rdc.2015.07.008 26476226
    [Google Scholar]
  4. Ritchlin C.T. Colbert R.A. Gladman D.D. Psoriatic Arthritis. N Engl J Med. 2017 376 10 957 970 10.1056/NEJMra1505557
    [Google Scholar]
  5. Eder L. Gladman D.D. Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies? Expert Rev. Clin. Immunol. 2014 10 6 763 770 10.1586/1744666X.2014.905741 24702706
    [Google Scholar]
  6. Cuéllar M.L. Citera G. Espinoza L.R. Treatment of psoriatic arthritis. Baillieres Clin. Rheumatol. 1994 8 2 483 498 10.1016/S0950‑3579(94)80030‑8 8076399
    [Google Scholar]
  7. Merola J.F. Lockshin B. Mody E.A. Switching biologics in the treatment of psoriatic arthritis. Semin. Arthritis Rheum. 2017 47 1 29 37 10.1016/j.semarthrit.2017.02.001 28363434
    [Google Scholar]
  8. Rida M.A. Lee K.A. Chandran V. Cook R.J. Gladman D.D. Persistence of Biologics in the Treatment of Psoriatic Arthritis: Data From a Large Hospital-Based Longitudinal Cohort. Arthritis Care Res. (Hoboken) 2023 75 10 2174 2181 10.1002/acr.25112 36913183
    [Google Scholar]
  9. Barnas J.L. Ritchlin C.T. Etiology and Pathogenesis of Psoriatic Arthritis. Rheum. Dis. Clin. North Am. 2015 41 4 643 663 10.1016/j.rdc.2015.07.006 26476224
    [Google Scholar]
  10. Vecellio M. Hake V.X. Davidson C. Carena M.C. Wordsworth B.P. Selmi C. The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis. Front. Immunol. 2021 11 596086 10.3389/fimmu.2020.596086 33574815
    [Google Scholar]
  11. Crispino N. Ciccia F. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin. Exp. Rheumatol. 2021 39 3 668 675 10.55563/clinexprheumatol/e7ayu8 33200731
    [Google Scholar]
  12. Traves P.G. Murray B. Campigotto F. Galien R. Meng A. Di Paolo J.A. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann. Rheum. Dis. 2021 80 7 865 875 10.1136/annrheumdis‑2020‑219012 33741556
    [Google Scholar]
  13. McInnes I.B. Kavanaugh A. Gottlieb A.B. Puig L. Rahman P. Ritchlin C. Brodmerkel C. Li S. Wang Y. Mendelsohn A.M. Doyle M.K. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013 382 9894 780 789 10.1016/S0140‑6736(13)60594‑2 23769296
    [Google Scholar]
  14. Ritchlin C. Rahman P. Kavanaugh A. McInnes I.B. Puig L. Li S. Wang Y. Shen Y.K. Doyle M.K. Mendelsohn A.M. Gottlieb A.B. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6- month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 2014 73 6 990 999 10.1136/annrheumdis‑2013‑204655 24482301
    [Google Scholar]
  15. Deodhar A. Helliwell P.S. Boehncke W.H. Kollmeier A.P. Hsia E.C. Subramanian R.A. Xu X.L. Sheng S. Agarwal P. Zhou B. Zhuang Y. Ritchlin C.T. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020 395 10230 1115 1125 10.1016/S0140‑6736(20)30265‑8 32178765
    [Google Scholar]
  16. Mease P.J. Rahman P. Gottlieb A.B. Kollmeier A.P. Hsia E.C. Xu X.L. Sheng S. Agarwal P. Zhou B. Zhuang Y. van der Heijde D. McInnes I.B. Guselkumab in biologic- naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020 395 10230 1126 1136 10.1016/S0140‑6736(20)30263‑4 32178766
    [Google Scholar]
  17. Coates L.C. Ritchlin C.T. Gossec L. Helliwell P.S. Rahman P. Kollmeier A.P. Xu X.L. Shawi M. Karyekar C.S. Contré C. Noël W. Sheng S. Wang Y. Xu S. Mease P.J. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford) 2023 62 2 606 616 10.1093/rheumatology/keac375 35766811
    [Google Scholar]
  18. Coates L.C. Gossec L. Theander E. Bergmans P. Neuhold M. Karyekar C.S. Shawi M. Noël W. Schett G. McInnes I.B. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann. Rheum. Dis. 2022 81 3 359 369 10.1136/annrheumdis‑2021‑220991 34819273
    [Google Scholar]
  19. Schett G. Chen W. Gao S. Chakravarty S.D. Shawi M. Lavie F. Zimmermann M. Sharaf M. Coates L.C. Siebert S. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Res. Ther. 2023 25 1 150 10.1186/s13075‑023‑03125‑4 37587493
    [Google Scholar]
  20. Ritchlin C.T. Coates L.C. Mease P.J. van der Heijde D. Song J. Jiang Y. Shawi M. Kollmeier A.P. Rahman P. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. Trials 2023 24 1 22 10.1186/s13063‑022‑06945‑y 36627711
    [Google Scholar]
  21. Gladman D.D. Mease P.J. Bird P. Soriano E.R. Chakravarty S.D. Shawi M. Xu S. Quinn S.T. Gong C. Leibowitz E. Poddubnyy D. Tam L.S. Helliwell P.S. Kavanaugh A. Deodhar A. Østergaard M. Baraliakos X. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials 2022 23 1 743 10.1186/s13063‑022‑06589‑y 36064592
    [Google Scholar]
  22. Blair H.A. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis. Drugs 2020 80 12 1235 1245 10.1007/s40265‑020‑01357‑1 32632826
    [Google Scholar]
  23. Kristensen L.E. Keiserman M. Papp K. McCasland L. White D. Lu W. Wang Z. Soliman A.M. Eldred A. Barcomb L. Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann. Rheum. Dis. 2022 81 2 225 231 10.1136/annrheumdis‑2021‑221019 34911706
    [Google Scholar]
  24. Östör A. Van den Bosch F. Papp K. Asnal C. Blanco R. Aelion J. Alperovich G. Lu W. Wang Z. Soliman A.M. Eldred A. Barcomb L. Kivitz A. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann. Rheum. Dis. 2022 81 3 351 358 10.1136/annrheumdis‑2021‑221048 34815219
    [Google Scholar]
  25. Reich K. Papp K.A. Blauvelt A. Tyring S.K. Sinclair R. Thaçi D. Nograles K. Mehta A. Cichanowitz N. Li Q. Liu K. La Rosa C. Green S. Kimball A.B. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017 390 10091 276 288 10.1016/S0140‑6736(17)31279‑5 28596043
    [Google Scholar]
  26. Mease P.J. Chohan S. Fructuoso F.J.G. Luggen M.E. Rahman P. Raychaudhuri S.P. Chou R.C. Mendelsohn A.M. Rozzo S.J. Gottlieb A. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann. Rheum. Dis. 2021 80 9 1147 1157 10.1136/annrheumdis‑2020‑219014 33985942
    [Google Scholar]
  27. Gossec L. Kerschbaumer A. Ferreira R.J.O. Aletaha D. Baraliakos X. Bertheussen H. Boehncke W.H. Esbensen B.A. McInnes I.B. McGonagle D. Winthrop K.L. Balanescu A. Balint P.V. Burmester G.R. Cañete J.D. Claudepierre P. Eder L. Hetland M.L. Iagnocco A. Kristensen L.E. Lories R. Queiro R. Mauro D. Marzo-Ortega H. Mease P.J. Nash P. Wagenaar W. Savage L. Schett G. Shoop-Worrall S.J.W. Tanaka Y. Van den Bosch F.E. van der Helm-van Mil A. Zabotti A. van der Heijde D. Smolen J.S. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann. Rheum. Dis. 2024 83 6 ard-2024-225531 10.1136/ard‑2024‑225531 38499325
    [Google Scholar]
  28. Araujo e.g. Englbrecht M. Hoepken S. Finzel S. Kampylafka E. Kleyer A. Bayat S. Schoenau V. Hueber A. Rech J. Schett G. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin. Arthritis Rheum. 2019 48 4 632 637 10.1016/j.semarthrit.2018.05.011 30037432
    [Google Scholar]
  29. Yang K. Oak A.S.W. Elewski B.E. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am. J. Clin. Dermatol. 2021 22 2 173 192 10.1007/s40257‑020‑00578‑0 33301128
    [Google Scholar]
  30. Blauvelt A. Papp K.A. Griffiths C.E.M. Randazzo B. Wasfi Y. Shen Y.K. Li S. Kimball A.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial. J. Am. Acad. Dermatol. 2017 76 3 405 417 10.1016/j.jaad.2016.11.041 28057360
    [Google Scholar]
  31. Reich K. Armstrong A.W. Foley P. Song M. Wasfi Y. Randazzo B. Li S. Shen Y.K. Gordon K.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. J. Am. Acad. Dermatol. 2017 76 3 418 431 10.1016/j.jaad.2016.11.042 28057361
    [Google Scholar]
  32. Reich K. Gooderham M. Thaçi D. Crowley J.J. Ryan C. Krueger J.G. Tsai T.F. Flack M. Gu Y. Williams D.A. Thompson E.H.Z. Paul C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial. Lancet 2019 394 10198 576 586 10.1016/S0140‑6736(19)30952‑3 31280967
    [Google Scholar]
  33. Poddubnyy D. Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms. Drugs 2023 83 6 497 505 10.1007/s40265‑023‑01857‑w 36976477
    [Google Scholar]
  34. Baeten D. Østergaard M. Wei J.C.C. Sieper J. Järvinen P. Tam L.S. Salvarani C. Kim T.H. Solinger A. Datsenko Y. Pamulapati C. Visvanathan S. Hall D.B. Aslanyan S. Scholl P. Padula S.J. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. 2018 77 9 1295 1302 10.1136/annrheumdis‑2018‑213328 29945918
    [Google Scholar]
  35. Deodhar A. Gensler L.S. Sieper J. Clark M. Calderon C. Wang Y. Zhou Y. Leu J.H. Campbell K. Sweet K. Harrison D.D. Hsia E.C. van der Heijde D. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol. 2019 71 2 258 270 10.1002/art.40728 30225992
    [Google Scholar]
  36. Kavanaugh A. Puig L. Gottlieb A.B. Ritchlin C. You Y. Li S. Song M. Randazzo B. Rahman P. McInnes I.B. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann. Rheum. Dis. 2016 75 11 1984 1988 10.1136/annrheumdis‑2015‑209068 27098404
    [Google Scholar]
  37. Mease P.J. Helliwell P.S. Gladman D.D. Poddubnyy D. Baraliakos X. Chakravarty S.D. Kollmeier A.P. Hsia E.C. Xu X.L. Sheng S. Agarwal P. Zhou B. Sweet K. Shawi M. Karyekar C.S. Deodhar A. van der Heijde D. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021 3 10 e715 e723 10.1016/S2665‑9913(21)00105‑3 38287608
    [Google Scholar]
  38. Braun J. Landewé R.B.M. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’? Ann. Rheum. Dis. 2022 81 4 466 468 10.1136/annrheumdis‑2021‑221422 34656991
    [Google Scholar]
  39. Poddubnyy D Baraliakos X Van Den Bosch F Braun J Coates LC Chandran V Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther Adv Musculoskelet Dis. 2021 13 1759720X2110579
    [Google Scholar]
  40. Ruggiero A. Potestio L. Camela E. Snr Fabbrocini G. Megna M. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis (Auckl.) 2022 12 127 137 10.2147/PTT.S367744 35707807
    [Google Scholar]
  41. McInnes I.B. Asahina A. Coates L.C. Landewé R. Merola J.F. Ritchlin C.T. Tanaka Y. Gossec L. Gottlieb A.B. Warren R.B. Ink B. Assudani D. Bajracharya R. Shende V. Coarse J. Mease P.J. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 2023 401 10370 25 37 10.1016/S0140‑6736(22)02302‑9 36493791
    [Google Scholar]
  42. Merola J.F. Landewé R. McInnes I.B. Mease P.J. Ritchlin C.T. Tanaka Y. Asahina A. Behrens F. Gladman D.D. Gossec L. Gottlieb A.B. Thaçi D. Warren R.B. Ink B. Assudani D. Bajracharya R. Shende V. Coarse J. Coates L.C. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet 2023 401 10370 38 48 10.1016/S0140‑6736(22)02303‑0 36495881
    [Google Scholar]
  43. Coates L.C. McInnes I.B. Merola J.F. Warren R.B. Kavanaugh A. Gottlieb A.B. Gossec L. Assudani D. Bajracharya R. Coarse J. Ink B. Ritchlin C.T. Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study. Arthritis Rheumatol. 2022 74 12 1959 1970 10.1002/art.42280 35829656
    [Google Scholar]
  44. Mease P.J. Smolen J.S. Behrens F. Nash P. Liu Leage S. Li L. Tahir H. Gooderham M. Krishnan E. Liu-Seifert H. Emery P. Pillai S.G. Helliwell P.S. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann. Rheum. Dis. 2020 79 1 123 131 10.1136/annrheumdis‑2019‑215386 31563894
    [Google Scholar]
  45. McInnes I.B. Behrens F. Mease P.J. Kavanaugh A. Ritchlin C. Nash P. Masmitja J.G. Goupille P. Korotaeva T. Gottlieb A.B. Martin R. Ding K. Pellet P. Mpofu S. Pricop L. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020 395 10235 1496 1505 10.1016/S0140‑6736(20)30564‑X 32386593
    [Google Scholar]
  46. Warren R.B. Blauvelt A. Bagel J. Papp K.A. Yamauchi P. Armstrong A. Langley R.G. Vanvoorden V. De Cuyper D. Cioffi C. Peterson L. Cross N. Reich K. Bimekizumab versus Adalimumab in Plaque Psoriasis. N. Engl. J. Med. 2021 385 2 130 141 10.1056/NEJMoa2102388 33891379
    [Google Scholar]
  47. Blauvelt A. Reich K. Tsai T.F. Tyring S. Vanaclocha F. Kingo K. Ziv M. Pinter A. Vender R. Hugot S. You R. Milutinovic M. Thaçi D. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J. Am. Acad. Dermatol. 2017 76 1 60 69.e9 10.1016/j.jaad.2016.08.008 27663079
    [Google Scholar]
  48. Reich K. Pinter A. Lacour J.P. Ferrandiz C. Micali G. French L.E. Lomaga M. Dutronc Y. Henneges C. Wilhelm S. Hartz S. Paul C. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br. J. Dermatol. 2017 177 4 1014 1023 10.1111/bjd.15666 28542874
    [Google Scholar]
  49. Reich K. Papp K.A. Blauvelt A. Langley R.G. Armstrong A. Warren R.B. Gordon K.B. Merola J.F. Okubo Y. Madden C. Wang M. Cioffi C. Vanvoorden V. Lebwohl M. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021 397 10273 487 498 10.1016/S0140‑6736(21)00125‑2 33549193
    [Google Scholar]
  50. Thaçi D. Blauvelt A. Reich K. Tsai T.F. Vanaclocha F. Kingo K. Ziv M. Pinter A. Hugot S. You R. Milutinovic M. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J. Am. Acad. Dermatol. 2015 73 3 400 409 10.1016/j.jaad.2015.05.013 26092291
    [Google Scholar]
  51. Lebwohl M. Strober B. Menter A. Gordon K. Weglowska J. Puig L. Papp K. Spelman L. Toth D. Kerdel F. Armstrong A.W. Stingl G. Kimball A.B. Bachelez H. Wu J.J. Crowley J. Langley R.G. Blicharski T. Paul C. Lacour J.P. Tyring S. Kircik L. Chimenti S. Callis Duffin K. Bagel J. Koo J. Aras G. Li J. Song W. Milmont C.E. Shi Y. Erondu N. Klekotka P. Kotzin B. Nirula A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N. Engl. J. Med. 2015 373 14 1318 1328 10.1056/NEJMoa1503824 26422722
    [Google Scholar]
  52. Reich K. Warren R.B. Lebwohl M. Gooderham M. Strober B. Langley R.G. Paul C. De Cuyper D. Vanvoorden V. Madden C. Cioffi C. Peterson L. Blauvelt A. Bimekizumab versus Secukinumab in Plaque Psoriasis. N. Engl. J. Med. 2021 385 2 142 152 10.1056/NEJMoa2102383 33891380
    [Google Scholar]
  53. Reich K. Armstrong A.W. Langley R.G. Flavin S. Randazzo B. Li S. Hsu M.C. Branigan P. Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019 394 10201 831 839 10.1016/S0140‑6736(19)31773‑8 31402114
    [Google Scholar]
  54. Blauvelt A. Papp K. Gottlieb A. Jarell A. Reich K. Maari C. Gordon K.B. Ferris L.K. Langley R.G. Tada Y. Lima R.G. Elmaraghy H. Gallo G. Renda L. Park S.Y. Burge R. Bagel J. Vender R. Lomaga M.A. Delorme I. Hong C-H. Langley R.L. Albrecht L. Guenther L. Maari C. Papp K. Singh Ohson K.K. Barber K. Lynde C. Gupta A. Rosoph L. Gauthier J-S. Gooderham M. Wasel N. Raman M. Wiseman M. Greenstein D. Jarell A. Moon C. Clark L. Jazayeri S.S. Bukhalo M. Moore A. Hamilton T.K. Gewirtzman A. Hazan L. Crowley J. Teller C. Zirwas M. Smith S.R. Christine Lee M. Tyring S. Lee P. Dhawan S. Leonardi C. Jesus A.P-D. McFalda W. Frankel E. Yamauchi P. Fretzin S. Serrao R. Schlesinger T. Gottlieb S. Jenkin P. Gharib R. Davis S. Nami N. Draelos Z.D. Godwin L. Owen C. Landis M. Abramovits W. Sanchez-Rivera S. Van Voorhees A. Fivenson D. Kerdel F. Forman S.B. Weinberg J. Gonzalez-Chavez J. Boyce B. Stein-Gold L. Hudson C. Brown C. Coggi J. Feser C. Forconi R. Johnson S. McCune M. Green L. Madkan V. Shipp D.M. Gordon K. Waibel J. Soto-Raices O. Cather J. Miller S. Scott J. Young D. Kaffenberger J. Yokum K. Zook M. Blauvelt A. Truett A. Schmieder G. McCracken G. McElgunn P. Herrmann J. Suchniak J.M. Appel J. Barranco E. Lee M. Bagel J. Osman L. Cauthen A. Sadick N. De La Torre E. Taylor K. Cohen D. Harris H.H. Soung J. Dimitropoulos V. Miller S. Barnes C. Jumean-Haddad R. Bruce S. Cheung L. Guenthner S. Gaspari A. Laquer V. Krell J.M. Jacobs S. Nahm W. Korman N. Elewski B. Ferris L. Duffin K.C. Pariser D. Johnson B. Wallace P. Travers J. Fried R. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br. J. Dermatol. 2020 182 6 1348 1358 10.1111/bjd.18851 31887225
    [Google Scholar]
  55. Blauvelt A. Leonardi C. Elewski B. Crowley J.J. Guenther L.C. Gooderham M. Langley R.G. Vender R. Pinter A. Griffiths C.E.M. Tada Y. Elmaraghy H. Lima R.G. Gallo G. Renda L. Burge R. Park S.Y. Zhu B. Papp K. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br. J. Dermatol. 2021 184 6 1047 1058 10.1111/bjd.19509 32880909
    [Google Scholar]
  56. Warren R.B. Blauvelt A. Poulin Y. Beeck S. Kelly M. Wu T. Geng Z. Paul C. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy–assessor-blinded clinical trial. Br. J. Dermatol. 2021 184 1 50 59 10.1111/bjd.19341 32594522
    [Google Scholar]
  57. Ramiro S. Nikiphorou E. Sepriano A. Ortolan A. Webers C. Baraliakos X. Landewé R.B.M. Van den Bosch F.E. Boteva B. Bremander A. Carron P. Ciurea A. van Gaalen F.A. Géher P. Gensler L. Hermann J. de Hooge M. Husakova M. Kiltz U. López-Medina C. Machado P.M. Marzo-Ortega H. Molto A. Navarro-Compán V. Nissen M.J. Pimentel-Santos F.M. Poddubnyy D. Proft F. Rudwaleit M. Telkman M. Zhao S.S. Ziade N. van der Heijde D. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 2023 82 1 19 34 10.1136/ard‑2022‑223296 36270658
    [Google Scholar]
  58. Baraliakos X. Gossec L. Pournara E. Jeka S. Mera-Varela A. D’Angelo S. Schulz B. Rissler M. Nagar K. Perella C. Coates L.C. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann. Rheum. Dis. 2021 80 5 582 590 10.1136/annrheumdis‑2020‑218808 33334727
    [Google Scholar]
  59. Deodhar A Gladman D Bolce R Sandoval D Park SY Leage SL The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Ther Adv Musculoskelet Dis. 2023 15 1759720X231189005
    [Google Scholar]
  60. McInnes I.B. Anderson J.K. Magrey M. Merola J.F. Liu Y. Kishimoto M. Jeka S. Pacheco-Tena C. Wang X. Chen L. Zueger P. Liu J. Pangan A.L. Behrens F. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N. Engl. J. Med. 2021 384 13 1227 1239 10.1056/NEJMoa2022516 33789011
    [Google Scholar]
  61. Mease P.J. Lertratanakul A. Anderson J.K. Papp K. Van den Bosch F. Tsuji S. Dokoupilova E. Keiserman M. Wang X. Zhong S. McCaskill R.M. Zueger P. Pangan A.L. Tillett W. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann. Rheum. Dis. 2021 80 3 312 320 10.1136/annrheumdis‑2020‑218870 33272960
    [Google Scholar]
  62. McInnes I.B. Kato K. Magrey M. Merola J.F. Kishimoto M. Pacheco-Tena C. Haaland D. Chen L. Duan Y. Zueger P. Liu J. Lippe R. Pangan A.L. Behrens F. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open 2021 7 3 e001838 10.1136/rmdopen‑2021‑001838 34663636
    [Google Scholar]
  63. Armstrong A.W. Gooderham M. Warren R.B. Papp K.A. Strober B. Thaçi D. Morita A. Szepietowski J.C. Imafuku S. Colston E. Throup J. Kundu S. Schoenfeld S. Linaberry M. Banerjee S. Blauvelt A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J. Am. Acad. Dermatol. 2023 88 1 29 39 10.1016/j.jaad.2022.07.002 35820547
    [Google Scholar]
  64. Strober B. Thaçi D. Sofen H. Kircik L. Gordon K.B. Foley P. Rich P. Paul C. Bagel J. Colston E. Throup J. Kundu S. Sekaran C. Linaberry M. Banerjee S. Papp K.A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J. Am. Acad. Dermatol. 2023 88 1 40 51 10.1016/j.jaad.2022.08.061 36115523
    [Google Scholar]
  65. Mease P.J. Deodhar A.A. van der Heijde D. Behrens F. Kivitz A.J. Neal J. Kim J. Singhal S. Nowak M. Banerjee S. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann. Rheum. Dis. 2022 81 6 815 822 10.1136/annrheumdis‑2021‑221664 35241426
    [Google Scholar]
  66. Berekmeri A. Mahmood F. Wittmann M. Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev. Clin. Immunol. 2018 14 9 719 730 10.1080/1744666X.2018.1512404 30118353
    [Google Scholar]
  67. Edwards C.J. Blanco F.J. Crowley J. Birbara C.A. Jaworski J. Aelion J. Stevens R.M. Vessey A. Zhan X. Bird P. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann. Rheum. Dis. 2016 75 6 1065 1073 10.1136/annrheumdis‑2015‑207963 26792812
    [Google Scholar]
  68. Papp K. Cather J.C. Rosoph L. Sofen H. Langley R.G. Matheson R.T. Hu C. Day R.M. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012 380 9843 738 746 10.1016/S0140‑6736(12)60642‑4 22748702
    [Google Scholar]
  69. Deodhar A. Poddubnyy D. Pacheco-Tena C. Salvarani C. Lespessailles E. Rahman P. Järvinen P. Sanchez-Burson J. Gaffney K. Lee E.B. Krishnan E. Santisteban S. Li X. Zhao F. Carlier H. Reveille J.D. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2019 71 4 599 611 10.1002/art.40753 30343531
    [Google Scholar]
  70. van der Heijde D. Cheng-Chung Wei J. Dougados M. Mease P. Deodhar A. Maksymowych W.P. Van den Bosch F. Sieper J. Tomita T. Landewé R. Zhao F. Krishnan E. Adams D.H. Pangallo B. Carlier H. Churchill M. Flint K. Gladstein G. Greenwald M. Howell M. Ince A. Kaine J. Mehta D. Peters E. Querubin R. Reveille J. Roseff R. Diegel R. Thai C. Bessette L. Morin F. Rahman P. Barrera Rodriguez A.A. Cons-Molina F. Duran Barragan S. Skinner C. Pacheco Tena C. Ramos Remus C. Rizo Rodriguez J.C. Hong S-J. Lee Y-A. Ju J.H. Kang S.W. Kim T-H. Lee C.K. Lee E.B. Lee S.H. Park M-C. Shin K. Lee S-H. Chen H-A. Chen Y-C. Hsieh S-C. Lan J-L. Dvorak Z. Moravcova R. Malcova M. Taniguchi Y. Kishimoto M. Tada K. Dobashi H. Inui K. Ueki Y. Matsumoto Y. Koyama Y. Hatta K. Atsumi T. Goto H. Matsui K. Takakubo Y. Neeck G. Poddubnyy D. Rubbert-Roth A. Szymanska M. Blicharski T. Dudek A. Racewicz A. Wojciechowski R. van de Sande M. Griep E. Nurmohamed M. Matsievskaya G. Shmidt E. Stanislav M. Yakushin S. Ershova O. Rebrov A. Balazs T. Cseuz R. Drescher E. Poor G. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 2018 392 10163 2441 2451 10.1016/S0140‑6736(18)31946‑9 30360964
    [Google Scholar]
  71. Deodhar A. Sliwinska-Stanczyk P. Xu H. Baraliakos X. Gensler L.S. Fleishaker D. Wang L. Wu J. Menon S. Wang C. Dina O. Fallon L. Kanik K.S. van der Heijde D. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 2021 80 8 1004 1013 10.1136/annrheumdis‑2020‑219601 33906853
    [Google Scholar]
  72. van der Heijde D. Song I.H. Pangan A.L. Deodhar A. van den Bosch F. Maksymowych W.P. Kim T.H. Kishimoto M. Everding A. Sui Y. Wang X. Chu A.D. Sieper J. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019 394 10214 2108 2117 10.1016/S0140‑6736(19)32534‑6 31732180
    [Google Scholar]
  73. Baraliakos X. Ranza R. Östör A. Ciccia F. Coates L.C. Rednic S. Walsh J.A. Douglas K. Gao T. Kato K. Song I.H. Ganz F. Deodhar A. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res. Ther. 2023 25 1 56 10.1186/s13075‑023‑03027‑5 37038159
    [Google Scholar]
  74. Proft F. Torgutalp M. Muche B. Rios Rodriguez V. Verba M. Poddubnyy D. Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial. BMJ Open 2021 11 11 e048647 10.1136/bmjopen‑2021‑048647 34785545
    [Google Scholar]
  75. Hamilton T.K. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J. Drugs Dermatol. 2008 7 11 1089 1093 19110745
    [Google Scholar]
  76. Rathod D. Weinberg J.M. Yamauchi P.S. Kircik L.H. Wollina U. Lotti T. Goldust M. Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report. J. Drugs Dermatol. 2019 18 4 394 396 31017383
    [Google Scholar]
  77. Heinecke G.M. Luber A.J. Levitt J.O. Lebwohl M.G. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J. Drugs Dermatol. 2013 12 10 1098 1102 24085044
    [Google Scholar]
  78. Thibodeaux Q. Ly K. Reddy V. Smith M.P. Liao W. Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Rep. 2019 5 10 928 930 10.1016/j.jdcr.2019.08.015 31649982
    [Google Scholar]
  79. Cuchacovich R Garcia-Valladares I Espinoza LR Combination Biologic Treatment of Refractory Psoriasis and Psoriatic Arthritis. J Rheumatol. 2012 39 1 187 193
    [Google Scholar]
  80. Genovese M.C. Cohen S. Moreland L. Lium D. Robbins S. Newmark R. Bekker P. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004 50 5 1412 1419 10.1002/art.20221 15146410
    [Google Scholar]
  81. Alharbi S. Ye J.Y. Lee K.A. Chandran V. Cook R.J. Gladman D.D. Remission in psoriatic arthritis: Definition and predictors. Semin. Arthritis Rheum. 2020 50 6 1494 1499 10.1016/j.semarthrit.2020.01.012 32145969
    [Google Scholar]
  82. Coates L.C. Cook R. Lee K.A. Chandran V. Gladman D.D. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res. (Hoboken) 2010 62 7 970 976 10.1002/acr.20162 20191569
    [Google Scholar]
  83. Ye W. Tucker L.J. Coates L.C. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity. Drugs 2018 78 16 1705 1715 10.1007/s40265‑018‑0994‑3 30341684
    [Google Scholar]
  84. Haddad A. Thavaneswaran A. Ruiz-Arruza I. Pellett F. Chandran V. Cook R.J. Gladman D.D. Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res. (Hoboken) 2015 67 6 842 847 10.1002/acr.22529 25469741
    [Google Scholar]
  85. Araujo e.g. Finzel S. Englbrecht M. Schreiber D.A. Faustini F. Hueber A. Nas K. Rech J. Schett G. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann. Rheum. Dis. 2015 74 4 655 660 10.1136/annrheumdis‑2013‑204229 24336010
    [Google Scholar]
  86. Coates L.C. Pillai S.G. Tahir H. Valter I. Chandran V. Kameda H. Okada M. Kerr L. Alves D. Park S.Y. Adams D.H. Gallo G. Hufford M.M. Hojnik M. Mease P.J. Kavanaugh A. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study. Arthritis Rheumatol. 2021 73 9 1663 1672 10.1002/art.41716 33682378
    [Google Scholar]
  87. Huynh D.H. Boyd T.A. Etzel C.J. Cox V. Kremer J. Mease P. Kavanaugh A. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open 2017 3 1 e000395 10.1136/rmdopen‑2016‑000395 28123783
    [Google Scholar]
  88. Michielsens C.A.J. den Broeder N. van den Hoogen F.H.J. Mahler E.A.M. Teerenstra S. van der Heijde D. Verhoef L.M. den Broeder A.A. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Ann. Rheum. Dis. 2022 81 10 1392 1399 10.1136/annrheumdis‑2022‑222260 35701155
    [Google Scholar]
  89. Nagy G. Roodenrijs N.M.T. Welsing P.M.J. Kedves M. Hamar A. van der Goes M.C. Kent A. Bakkers M. Blaas E. Senolt L. Szekanecz Z. Choy E. Dougados M. Jacobs J.W.G. Geenen R. Bijlsma H.W.J. Zink A. Aletaha D. Schoneveld L. van Riel P. Gutermann L. Prior Y. Nikiphorou E. Ferraccioli G. Schett G. Hyrich K.L. Mueller-Ladner U. Buch M.H. McInnes I.B. van der Heijde D. van Laar J.M. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann. Rheum. Dis. 2021 80 1 31 35 10.1136/annrheumdis‑2020‑217344 33004335
    [Google Scholar]
  90. Griffiths C.E.M. Thaçi D. Gerdes S. Arenberger P. Pulka G. Kingo K. Weglowska J. Hattebuhr N. Poetzl J. Woehling H. Wuerth G. Afonso M. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br. J. Dermatol. 2017 176 4 928 938 10.1111/bjd.15152 27787890
    [Google Scholar]
  91. Papp K. Bachelez H. Costanzo A. Foley P. Gooderham M. Kaur P. Narbutt J. Philipp S. Spelman L. Weglowska J. Zhang N. Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J. Am. Acad. Dermatol. 2017 76 6 1093 1102 10.1016/j.jaad.2016.12.014 28291552
    [Google Scholar]
/content/journals/crr/10.2174/0115733971339350240830104424
Loading
Updates on Recent Advances in the Therapy of Adult Psoriatic Disease
Bentham Science Publishers ; https://doi.org/10.2174/0115733971339350240830104424
/content/journals/crr/10.2174/0115733971339350240830104424
/content/journals/crr/10.2174/0115733971339350240830104424
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords:  psoriasis ;  axial  disease ; Psoriatic  arthritis ;  advances ;  disease-modifying  anti-rheumatic  drugs ; withdrawal  of therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test